Estrogen Receptor-Positive Breast Cancer Patient-Derived Xenografts
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT02752893
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Brief Summary
The investigators will establish a platform at Dartmouth-Hitchcock Medical Center to generate novel models of estrogen receptor alpha-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer, which will be used for research studies to develop novel treatment strategies and dissect signaling pathways underlying drug sensitivity and resistance.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Xenograft success rate, defined as the percentage of patient tumors that yield a growing xenograft in mice. 1 year from time of surgery
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Dartmouth-Hitchcock Medical Center
🇺🇸Lebanon, New Hampshire, United States